Evidence map›Paper›PMID 23297258›Full record

ReviewClinical microbiology reviews2013

Evidence and implications of mortality associated with acute Plasmodium vivax malaria.

J Kevin Baird

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical microbiology reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05071079 (A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults), which is not on this map. Cited by 237 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 8 pooled it
37.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05071079 narecruitingnot on this mapstarted 2022, after this paper: background citation

A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults

TypeinterventionalSponsorUniversity of OxfordRan2022 to 2026Enrolled48ConditionsPlasmodium Vivax InfectionArmsAn inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum
3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 8 syntheses or guidelines pooled it, 404 citations in OpenAlex.

  1. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Respiratory Complications ofThe American journal of tropical medicine and hygiene · 2017
    Pooled it
  6. The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials.International journal for parasitology. Drugs and drug resistance · 2017
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Observational
  13. Article
  14. Article
  15. An Increase in ImportedOpen forum infectious diseases · 2026
    Article
  16. Article
  17. Article
  18. Naturally acquired antibodies toFrontiers in immunology · 2026
    Article
  19. Article
  20. Article

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

J Kevin BairdEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and the Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Eijkman Institute for Molecular Biology · ID

Funding

Wellcome Trust 089276Wellcome Trust B9RJIXO
6 · The paper itself

Abstract

Vivax malaria threatens patients despite relatively low-grade parasitemias in peripheral blood. The tenet of death as a rare outcome, derived from antiquated and flawed clinical classifications, disregarded key clinical evidence, including (i) high rates of mortality in neurosyphilis patients treated with vivax malaria; (ii) significant mortality from zones of endemicity; and (iii) the physiological threat inherent in repeated, very severe paroxysms in any patient, healthy or otherwise. The very well-documented course of this infection, with the exception of parasitemia, carries all of the attributes of "perniciousness" historically linked to falciparum malaria, including severe disease and fatal outcomes. A systematic analysis of the parasite biomass in severely ill patients that includes blood, marrow, and spleen may ultimately explain this historic misunderstanding. Regardless of how this parasite is pernicious, recent data demonstrate that the infection comes with a significant burden of morbidity and associated mortality. The extraordinary burden of malaria is not heavily weighted upon any single continent by a single species of parasite-it is a complex problem for the entire endemic world, and both species are of fundamental importance. Humanity must rally substantial resources, intellect, and energy to counter this daunting but profound threat.

Indexed as

BloodBone MarrowHumansMalaria, VivaxParasitemiaPlasmodium vivaxSpleen

Identifiers

PMID23297258
PMCPMC3553673
OpenAlexW2134054893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.